U.S. Supreme Court takes up Texas case challenging abortion pill access

By Eleanor KlibanoffOriginally appeared in the Texas Tribune A majority of Supreme Court justices seemed open to keeping mifepristone, a common abortion-inducing drug, on the market despite a Texas ruling revoking its FDA approval. In arguments Tuesday, the U.S. Supreme Court indicated there may be a majority of justices willing to preserve access to mifepristone, a common abortion-inducing drug. This is the first major abortion case the high court has heard since& it& overturned Roe v. Wade in 2022. The case was first filed in Amarillo, where& conservative federal Judge Matthew Kacsmaryk& sided& nearly a year ago with anti-abortion groups seeking to move mifepristone off the market. Subsequently, the Supreme Court& froze& any changes to the drug’s legal status until it had a chance to hear the case. The Alliance for Hippocratic Medicine, an organization of anti-abortion doctors, filed the initial lawsuit in November 2022, saying the U.S. Food and Drug Administration did not properly vet the safety of mifepristone before approving it in 2000 or loosening restrictions in 2016 and 2022. In their filings, the FDA and Danco Laboratories, which produces mifepristone, point to decades of overwhelming evidence that shows the safety and efficacy of mifepristone. But the arguments...